21 2026 RNDS Гринберг, Леви, экспертная панель «Состояние науки» брендированная

In this session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), Michael Levy, MD, PhD, of Massachusetts General Hospital and Benjamin Greenberg, MD, MHS, of the University of Texas Southwestern talked through the state of the science across rare neuroimmune disorders and clinical trials [00:00:05]. They started with epidemiology maps, what they can show about possible genetic hotspots, and why a place with no dots may simply lack access to antibody testing [00:00:57]. They discussed how genetics, environment, and timing may combine to cause these disorders [00:05:15], then how immune activity outside the nervous system may move in and out of it [00:07:48]. They explained why antibodies are more complicated than a single positive test, and how an antibody can be present during remission [00:10:46]. They covered MRI, blood tests, false negatives, and spinal fluid testing [00:20:24], and closed with MOGAD trials, insurance case managers, future therapies, and audience questions [00:31:38]. Benjamin Greenberg, MD, MHS, is Director of the Perot Foundation Neurosciences Translational Research Center within the O'Donnell Brain Institute and Vice Chair of Translational Research for the Department of Neurology at University of Texas Southwestern Medical Center. He directs the Transverse Myelitis and Neuromyelitis Optica Program and established the Pediatric Demyelinating Disease Program at Children's Medical Center Dallas in 2009. He is recognized internationally as an expert in rare autoimmune disorders of the central nervous system. Michael Levy, MD, PhD, is an Associate Neurologist at Massachusetts General Hospital and Research Director of the Division of Neuroimmunology and Neuroinfectious Disease. He completed the MD/PhD program at Baylor College of Medicine and trained at Johns Hopkins, where he started the Neuromyelitis Optica Clinic and Research Laboratory. In 2019, he moved to Massachusetts General Hospital and Harvard Medical School to develop the research program in neuroimmunology. 00:00 Welcome and Panel Introductions 00:57 Epidemiology and Global Maps 05:15 Genetics, Environment, and Timing 07:48 How These Disorders Develop 10:46 Why Antibodies Are Complicated 16:25 Antibodies and Remission 20:24 MRI in Daily Care 24:39 Blood Tests and Antibody Assays 29:44 Spinal Fluid Testing 31:38 Clinical Trials Overview 33:58 Trials and Treatment Decisions 39:44 Insurance Case Managers 41:12 Future Therapies 42:54 Audience Questions and Closing